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Abstract
We have compared the efficacy of inhibition of the cytochrome bc1 complexes from yeast and bovine heart mitochondria and Paracoccus
denitrificans by antimycin, ilicicolin H, and funiculosin, three inhibitors that act at the quinone reduction site at center N of the enzyme. Although
the three inhibitors have some structural features in common, they differ significantly in their patterns of inhibition. Also, while the overall folding
pattern of cytochrome b around center N is similar in the enzymes from the three species, amino acid sequence differences create sufficient
structural differences so that there are striking differences in the inhibitors binding to the three enzymes. Antimycin is the most tightly bound of the
three inhibitors, and binds stoichiometrically to the isolated enzymes from all three species under the cytochrome c reductase assay conditions.
Ilicicolin H also binds stoichiometrically to the yeast enzyme, but binds approximately 2 orders of magnitude less tightly to the bovine enzyme
and is essentially non-inhibitory to the Paracoccus enzyme. Funiculosin on the other hand inhibits the yeast and bovine enzymes similarly, with
IC50∼10 nM, while the IC50 for the Paracoccus enzyme is more than 10-fold higher. Similar differences in inhibitor efficacy were noted in bc1
complexes from yeast mutants with single amino acid substitutions at the center N site, although the binding affinity of quinone and quinol
substrates were not perturbed to a degree that impaired catalytic function in the variant enzymes. These results reveal a high degree of specificity
in the determinants of ligand-binding at center N, accompanied by sufficient structural plasticity for substrate binding as to not compromise center
N function. The results also demonstrate that, in principle, it should be possible to design novel inhibitors targeted toward center N of the bc1
complex with appropriate species selectivity to allow their use as drugs against pathogenic fungi and parasites.
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The cytochrome bc1 complex is a homodimeric, multisub-
unit enzyme embedded in the inner mitochondrial membrane of
oxygen utilizing eukaryotic cells and the plasma membrane
of many gram negative bacteria [1]. The catalytic core of the
enzyme is formed by the cytochrome b subunit, the Rieske
iron–sulfur protein and the cytochrome c1 subunit. In addition,Abbreviations: bL heme, low potential b heme; bH heme, high potential b
heme; DBH, decyl ubiquinol
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doi:10.1016/j.bbabio.2007.10.011the mitochondrial enzyme contains 6–8 supernumerary sub-
units lacking any cofactors, while the bacterial enzyme contains
none or one extra subunit [2]. The protonmotive Q cycle des-
cribes the mechanism by which the enzyme couples the transfer
of two electrons from quinol to two cytochrome c to the trans-
location of four protons across the membrane [3,4]. The Q cycle
involves two quinone binding sites in cytochrome b; the center
P (“QP”) site catalyzes quinol oxidation, with one electron
transferred to the Rieske protein en route to cytochromes c1 and
c, while the second electron is transferred to the low potential b
heme (bL) and recycled inward through the membrane to the
high potential heme (bH) to the opposite site of the membrane,
where it reduces quinone to form a tightly bound semiquinone
at the center N (QN) site.
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fically the QP or QN site [5]. These have been of use in the
structural and functional studies of the individual catalytic sites.
In addition, the QP inhibitor atovaquone [6] is of pharmaceutical
relevance for treatment of some parasitic and fungal infections.
Only a few center N specific inhibitors are known to date. These
include antimycin, which is a natural product of various species
of Streptomyces [7], ilicicolin H, isolated from the imperfect
fungus Cylindrocladium ilicicola [8,9], and funiculosin, pro-
duced by Penicillium funiculosum Thom [10,11]. Structurally
the inhibitors are clearly different, but they also share some
similarities [9]. Upon binding to the QN site, they all displace
semiquinone [12]. While ilicicolin H and antimycin both pos-
sess a phenol ring, funiculosin and ilicicolin H share a pyridone
ring system. Based on a similar optical effect of the latter two
inhibitors on the cytochrome bH spectrum, it was concluded that
the ring system plays an important role in their binding [9]. On
the other hand genetic studies in yeast indicate that the inhi-
bitors have different modes of binding to the bc1 complex [13].
In this study we have compared the inhibitory action of the
QN inhibitors, antimycin, funiculosin and ilicicolin H on the
cytochrome bc1 complexes from three different species, Sac-
charomyces cerevisiae, Bos taurus, and Paracoccus denitrifi-
cans. We also examined the inhibitor sensitivity of yeast bc1
complexes with center N mutations obtained from ilicicolin
H resistant [14] and respiratory deficient revertants [15,16]. The
results reveal striking differences in sensitivity of the enzymes
from the different species, and comparing the cytochrome b
sequences around the center N binding pocket allows some
preliminary speculation regarding the structural basis of the
differences in inhibitor efficacy between the species. The results
also demonstrate the feasibility of designing new therapeuticFig. 1. Comparison of the yeast and bovine cytochrome b protein structures in the reg
ubiquinone ring and amino acid residues 16–38 and 194–230 of the yeast protein o
carbon backbone of the yeast protein is colored cyan and the bH heme ring, ubiquinon
nitrogen atoms are blue, carbon atoms are green and sulfur is yellow. The carbon bac
water-mediated hydrogen bond between His-202, Ser-20, and the ubiquinone ring th
backbone of the bovine protein is colored cyan and the heme ring, ubiquinone ring, a
in panel A, while the yeast protein is depicted in grey. The figures were created fro
enzymes. (For interpretation of the references to color in this figure legend, the readdrugs, targeted to the bc1 complex, with species selectivity
based on structural differences in the center N of pathogens and
host enzymes.
2. Materials and methods
2.1. Materials
Dodecyl maltoside was obtained from Anatrace. DEAE-Biogel and Tween-
20 were obtained from Bio-Rad Laboratories. Antimycin, diisopropylfluoropho-
sphate, horse heart cytochrome c, and decyl ubiquinone were purchased from
Sigma Chemical Co. Dithionite was purchased from Fluka Biochemica. Decyl
ubiquinol (DBH) was prepared as described before and quantified spectro-
photometrically [17]. Funiculosin was a gift of Novartis, Basel, Switzerland.
Ilicicolin H was obtained from the Merck sample repository. The QN inhibitors
antimycin, ilicicolin and funiculosin were diluted in ethanol to a concentration of
50–200 μM.The extinction coefficients used to calculate the concentration of the
stock solutions were, for antimycin, 4.8 mM−1 cm−1 at 320 nm, for ilicicolin H,
5.3 mM−1 cm−1 at 349 nm, and for funiculosin 5.5 mM−1 cm−1 at 293 nm [5,9].
2.2. Purification of cytochrome bc1 complexes
The wild-type yeast strain with the KM91 background and the cytochrome
b mutants of that strain, M221Q, M221E and W30C were obtained from Dr.
Anne-Marie Colson (Universite Catholique de Louvain-La-Neuve, Belgium)
and Dr. Gael Brasseur (CNRS Marseille, France) [16,18]. The wild-type yeast
strain with the W303 background and cytochrome b mutants of that strain,
S20T, Q22E, Q22T and L198F, were described previously [14]. Bovine heart
mitochondria were a gift from Dr. Chang-an Yu (Oklahoma State University).
Cytochrome bc1 complexes from all of the yeast strains and bovine heart
mitochondrial membranes were purified as previously described [19]. Purified
cytochrome bc1 complex from P. denitrificans was a gift from Dr. Bernd
Ludwig (W. Goethe-Universität, Frankfurt am Main, Germany). The cyto-
chrome c1 concentration in the bc1 complexes was determined from the dif-
ference spectrum of the ascorbate-reduced versus ferricyanide-oxidized
enzymes, using an extinction coefficient of 17.5 mM−1 cm−1 at 554–539 nm.
The cytochrome b concentration was determined from the difference spectrumion of the proteins surrounding the QN site. Both panels show the bH hemes, the
verlaid with residues 17–39 and 193–229 of the bovine protein. In panel A the
e ring, and selected amino acids are labeled and colored. Oxygen atoms are red,
kbone and other features of the bovine protein are grey. Panel A also depicts the
at is present in the yeast, but not in the bovine, structure. In panel B the carbon
nd selected amino acids are labeled and colored according to the same scheme as
m the coordinates of the yeast (1EZV, Ref. [22]) and bovine (1ppj, Ref. [24])
er is referred to the web version of this article.)
Fig. 2. Sequence alignment of the cytochrome b proteins from bovine, yeast, P. denitrificans, chicken and eel in the regions forming the QN site. The sequences from
the latter two species were included since the enzymes from those species have been reported to be resistant to funiculosin, as discussed in the text. The alignment was
constructed using ClustalWand yeast numbering of residues 16–38 and 194–230. In the bovine enzyme the QN site is formed by residues 17–39 and 193–229, and in
the P. denitrificans enzyme by residues 31–53 and 208–252. The numbered arrows show the positions of the QN site yeast mutations that were analyzed, and the
residues His-202 and Asp-229.
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cients used were 50 mM−1 cm−1 at 562–578 nm for the yeast and bovine enzymes
[20,21], and 40 mM−1 cm−1 at 559–578 nm for the P. denitrificans bc1 complex.
2.3. Ubiquinol-cytochrome c reductase assay and inhibition by the
center N inhibitors antimycin, ilicicolin and funiculosin
Ubiquinol-cytochrome c reductase activities of the purified cytochrome bc1
complexes from bovine heart, commercially available Red Star™ yeast, and
P. denitrificans were measured at room temperature in an assay buffer con-
taining 50 mM potassium phosphate, pH 7.0, 250 mM sucrose, 1 mM sodium
azide, 0.2 mM EDTA, and 0.05% dodecyl maltoside. For the purified cyto-
chrome bc1 complexes from the other yeast strains, the assay buffer contained
50 mM potassium phosphate, pH 7.0, 1 mM sodium azide, 1 mM EDTA and
0.01% Tween-20. The dodecyl maltoside and Tween-20 were included in the
assay buffers because they improved the stability of the diluted enzyme during
the prolonged incubation required for equilibration with the inhibitors. The
enzymes were diluted first to ∼1 μM in 400 μL of the same assay buffer and
incubated on ice for 30 min. For measuring the activities, an aliquot of the
enzyme was diluted from the 1 μM sample to a final concentration of 2.5 nM in
an assay buffer containing 50 μM cytochrome c and 1 mM potassium cyanide
and incubated for 1.5 min. The reaction was started by adding 50 μMDBH, and
reduction of cytochrome c was monitored at 550–539 nm with the Aminco
DW2a™ spectrophotometer in the dual wavelength mode. The extinction
coefficient used to calculate the cytochrome c reduction was 21.5 mM−1cm−1 at
550–539 nm. All measurements were done in duplicate.
For measuring the inhibitor titration curves, the activity was first measured
without inhibitor and this was taken as 100% activity. The concentration of
inhibitor in the enzyme solution was increased incrementally by adding aliquots
from the inhibitor stock solutions to the 1 μM enzyme sample. After addition, the
enzyme–inhibitor solutionwas gentlymixed and incubated for 2min on ice prior to
measuring activity. The ethanol concentration in the solution did not exceed 5%.
3. Results
3.1. Comparison of the QN sites from yeast, bovine and
P. denitrificans bc1 complexes, and the location of yeastQNmutants
The QN site in the cytochrome bc1 complex from yeast [22]
and bovine [23,24] mitochondria is structurally highly con-
served (Fig. 1). Comparing the sequences of residues1 16–38
and 195–230 that form the QN site shows that ∼50% of the
amino acids are identical. No structural information is available1 Yeast numbering of the cytochrome b amino acid sequence is used
throughout, except when noted otherwise.for the complex from P. denitrificans, but the crystal structure of
the complex from Rhodobacter capsulatus [25], which
cytochrome b sequence is more than 80% conserved with that
of P. denitrificans, also shows a conserved structure of the QN
site. However the sequence identity of the bacterial enzyme
with those of the yeast and bovine enzymes is slightly lower,
∼35 and ∼45%, respectively. Interestingly, the sequence
identity of the residues that are present within 5 Å of the
ubiquinone (in the yeast structure) is no higher than the overall
identity in the center N pocket. It is striking that, even with this
degree of sequence variation, the distance and orientation of the
ubiquinone ring relative to the bH heme are essentially identical
in the yeast and bovine enzymes (Fig. 1). Five of the most
conserved residues near the ubiquinone are the axial histidine
ligand to the heme iron, His 197, two residues implicated in
quinone binding, His-202 and Asp-229, and Gly-33, Trp-30,
and Lys-228 [26]. It is also striking that the conserved His-202
participates in a water-mediated hydrogen bond to the quinone
ring in the yeast enzyme, but does not do so in the bovine
enzyme where it is rotated closer to the quinone. We have
studied here mutations of Trp-30, and four other residues, Ser-
20, Gln-22, Leu-198, and Met-221 that are less conserved, but
are within 5 Å of the ubiquinone ring.
Trp-30 forms a hydrogen bond with one of the propionate
groups of the bH heme (Fig. 1). The substitution of tryptophan by
a cysteine in theW30Cmutant has no natural equivalent. Leu-198
is conserved in the yeast and bovine enzymes (Figs. 1 and 2) and
is located close to the bH heme and the quinone. The analogous
residue in P. denitrificans is an isoleucine. The substitution of
leucine by phenylalanine in the L198F mutant is native in Can-
dida, but other hydrophobic residues are also observed. Inte-
restingly the L198F mutation was reported to confer resistance
towards the three center N inhibitors, antimycin, funiculosin and
ilicicolin H in the yeast enzyme [14]. It is not known whether the
Candida bc1 complex is intrinsically resistant to these center N
inhibitors.
A hydrophobic or van der Waals interaction is observed
between the residue at position 221 and the ubiquinone (Fig. 1).
In the complex from bovine mitochondria, P. denitrificans and
most other species the corresponding residue is a phenylalanine
(Fig. 2) [26]. The occurrence of methionine in the yeast bc1
Fig. 3. Inhibition of ubiquinol-cytochrome c reductase activity of yeast, P. denitrificans and bovine cytochrome bc1 complexes by the center N inhibitors antimycin
(panel A), ilicicolin H (panel B) and funiculosin (panel C). Activities are expressed as percentage of the activity of the corresponding non-inhibited enzymes. The
activities of the yeast bc1 complex are indicated with closed circles, those of the P. denitrificans bc1 complex with closed triangles, and those of the bovine bc1
complex with open circles. In the absence of inhibitor, the activities of the yeast, P. denitrificans and bovine enzymes were 125, 80 and 170 s−1, respectively. The
titration curves were obtained as described in Materials and methods. The dashed lines show the theoretical titration curves for the stoichiometric binding of one
inhibitor (antimycin and ilicicolin H) per bc1 complex. Structures of the inhibitors are shown above the titration curves.
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enzymes studied here contain substitutions that have not been
found in any cytochrome b sequences. The yeast strains with
these mutations were previously obtained as revertants of a
respiratory deficient mutant strain, M221K [27].
Ser-20 and Gln-22 from yeast are two of the least conserved
residues, but the results of an ilicicolin H resistance screen showedFig. 4. Inhibition of ubiquinol-cytochrome c reductase activity of yeast cytochrome b
the corresponding non-inhibited enzyme. In panel A the activities of W303 (wt) bc1
those of Q22Twith closed triangles, those of Q22E with open squares and those of L
(wt), S20T, Q22T, Q22E and L198F enzymes were 290, 140, 250, 260, 260 s−1, res
with closed circles, those of M221Q with open circles, those of M221E with closed
activities of the KM91, M221Q, M221E andW30C enzymes were 180, 150, 160 and
Materials and methods. The dashed lines show the theoretical titration curves for stoictheir importance in the center N function [14,28]. In the QN site of
yeast, these two residues are part of a hydrogen-bonding network
that also includes His-202, one carbonyl group of the ubiquinone,
and an active site water (Fig. 2A). In the bovine enzyme serine is
substituted by leucine and glutamine by an alanine. A structural
consequence of these substitutions appears to be rotation of the
histidine ring towards the ubiquinone, a direct hydrogen bondmutants by antimycin. Activities are expressed as percentage of the activity of
complex are indicated with closed circles, those of S20T with open diamonds,
198F with closed squares. In the absence of inhibitor, the activities of the W303
pectively. In panel B, the activities of the KM91 (wt) bc1 complex are indicated
squares and those of W30C with open triangles. In the absence of inhibitor, the
170 s−1, respectively. The inhibitor titration curves were obtained as described in
hiometric binding of one inhibitor (antimycin and ilicicolin H) per bc1 complex.
Fig. 5. Inhibition of ubiquinol-cytochrome c reductase activity of yeast cytochrome b mutants by ilicicolin H. The symbols used for the mutated enzymes in panels A
and B are the same as in Fig. 4. The dashed lines show the theoretical titration curves for the stoichiometric binding of one inhibitor per bc1 complex.
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[24] or indirectly through a water molecule [29]. The Leu-21
(bovine numbering) may also stabilize this histidine conformation.
In the P. denitrificans enzyme the residues at positions 20 and 22
are isoleucine and threonine, respectively. The crystal structure of
the R. capsulatus enzyme does not contain a ubiquinone bound at
the QN site, but the histidine has the same configuration as in the
bovine structure. Interestingly, substitutions of Ser-20 by a leucine,
or Gln-22 by a threonine rendered the yeast strains resistant to
ilicicolin H. Because the S20Lmutant bc1 complexwas reported to
be unstable [14], it has not been further characterized. However the
S20T, Q22T and Q22E mutants have been investigated.
3.2. Inhibition of yeast, bovine and P. denitrificans bc1
complexes by center N inhibitors
Fig. 3 compares the inhibition of cytochrome c reductase
activities of yeast, bovine and P. denitrificans bc1 complexes by
antimycin, ilicicolin H and funiculosin. The titration curves in
Fig. 3A show the inhibition of the three bc1 complexes by
antimycin. With one equivalent of antimycin more than 90% of
activity is inhibited in the bovine and yeast enzyme, as shown
before [9]. The P. denitrificans enzyme shows some residual
activity at higher concentration of antimycin, but the inhibitor
still effectively inactivates the enzyme. We previously reported
that ilicicolin H is a potent inhibitor for yeast bc1 complex, but
not for the bovine enzyme [9]. Under the assay conditions used
here, the residual catalytic activity is∼10% with one equivalent
of ilicicolin H per bc1 monomer. On the other hand, both the
bovine and P. denitrificans enzymes are highly resistant towards
this inhibitor (Fig. 3B), with IC50 values N100 nM for the
bovine enzyme while the bacterial enzyme is barely inhibited
even at the highest concentrations of inhibitor tested (data not
shown). For the yeast enzyme, funiculosin is the least effective
of the three inhibitors (Fig. 3C), and the titration curve for the
bovine enzyme is essentially identical to that the yeast complex.The Paracoccus enzyme is only weakly inhibited by this
inhibitor.
3.3. Inhibition of yeast cytochrome b mutants
The results in Fig. 4 show that none of the mutations affects
the inhibition of the isolated enzymes by antimycin; more than
90% of the catalytic activity is inhibited with a titer close to one
inhibitor per bc1 complex monomer. Thus the IC50 is still at
least an order of magnitude less than 2.5×10−9 M. The slight
hysteresis in the inhibitor titration of the bc1 complex from
wild-type yeast has been attributed by us to negative coope-
rativity between the two center N sites and inter-monomer
electron transfer through the bL hemes [30–32]. This same
behavior is seen with some of the cytochrome b mutant en-
zymes (Fig. 4). The lack of hysteresis in some of the mutant
enzymes suggests that the negative cooperativity might have
been weakened due to some of the mutations.
Ilicicolin H inhibits the cytochrome c reductase activity of
the KM91 and W303 wild-type strains ∼90% with a titer of one
inhibitor per bc1 monomer (Fig. 4), as is also observed with the
bc1 complex from commercial yeast (Fig. 3B). The S20T,
Q22E, Q22T and L198F mutations in the yeast bc1 complex that
conferred resistance to ilicicolin H, indeed provide significant
resistance towards this inhibitor (Fig. 5A). The Q22E mutant is
completely resistant with up to 40 equivalents (100 nM) of
inhibitor, whereas the other three mutations result in a gradual
decrease in catalytic activity with increasing concentration of
inhibitor. The M221E, M221Q and W30C mutants were not
obtained as yeast strains with resistance to ilicicolin in vivo, but
the purified enzymes from these mutants also do show re-
sistance to inhibition by this inhibitor (Fig. 5B), although to a
lesser extent than the other mutant enzymes.
With funiculosin the titration curves of the wild-type en-
zymes with the two genetic backgrounds appear to show some
difference; the W303 strain is more resistant towards this
Fig. 6. Inhibition of ubiquinol-cytochrome c reductase activity of yeast cytochrome b mutants by funiculosin. The symbols used for the mutated enzymes in panels A
and B are the same as in Fig. 4.
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at ∼8 versus ∼2 equivalents of inhibitor per bc1 monomer,
corresponding to IC50 values of 20 and 5 nM respectively.
However, with the exception of L198F andW30C, the mutations
appear to have no significant effect on the sensitivity to-
wards funiculosin. The bc1 complex with the L198F cytochrome
b mutation appears to be highly resistant, while the W30C
mutation appears only to be more resistant at higher concentra-
tions of funiculosin. Previous studies reported that both of these
mutations confer resistance to this inhibitor [33,34].
4. Discussion
In the current study we have compared the efficacy of three
center N inhibitors, antimycin, ilicicolin H and funiculosin
towards the purified cytochrome bc1 complexes from yeast,
bovine heart, and P. denitrificans. We also tested the efficacy of
the inhibitor against five variants of the yeast enzyme with
mutations in cytochrome b. Comparison of the sequences and
structures of the bc1 complexes from the three species showed
some common features for the binding of quinone and the
activity of center N. On the other hand, there are a number of
residues near the quinone that are not conserved. Previous
structural studies in the bovine enzyme [29] and genetic studies
in yeast [13] showed that the binding sites for different QN
inhibitors do not entirely overlap. We have probed the degree of
overlap more extensively with the center N mutations Ser-20,
Gln-22, Trp-30, Leu-198 and Met-221 in the yeast cytochrome
b. Analyzing these mutant enzymes allows some preliminary
conclusions to be made regarding the differences in efficacy of
the center N inhibitors against enzymes from the three different
species.
Antimycin has been known to bind with high affinity to the
bovine enzyme with an indirectly measured Kd=3.2×10
−11 M
[35]. In our experiments (Fig. 3A) we did not detect any
difference in the efficacy of inhibiting the catalytic activity ofthe bc1 complexes from the three species by this inhibitor.
Structural studies of the chicken [36] and bovine [24,29] bc1
complexes with antimycin bound show that the inhibitor is
similarly docked very close to the bH heme of cytochrome b in
the two enzymes. Indeed, two of the most conserved residues
(see Fig. 2 and Ref. [26]), Lys-228 and Asp-229, have been
implicated in the strong binding of this inhibitor [29]. In the
crystal structures of the chicken [36] and bovine [24,29] bc1
complexes these two residues form hydrogen bonds with the
inhibitor, directly or through structural waters. A hydrophobic
interaction that is observed between ubiquinone and Met-221
(Phe in bovine and P. denitrificans, Figs. 1 and 2) may also
contribute to the binding of this inhibitor, but this appears not to
be essential (see below).
Likewise, none of the center N mutations in the yeast
dramatically affects the sensitivity of the yeast enzyme for
antimycin (Fig. 4). However, it should be noted that under the
assay conditions employed in our experiments, an increase of as
much as 50-fold from the Kd=3.2×10
−11 M estimated for the
bovine enzyme would go undetected, since the concentration of
enzyme is 2.5×10−9 M in the assay. This might explain why the
L198F mutant, although resistant towards antimycin in vivo
[14], was inhibited by a titer of ∼1 antimycin per bc1 monomer.
The M221E and M221Q mutations also did not change the
sensitivity to antimycin in our experiments, while a M221K
mutation in the same parental strain blocked antimycin binding
to the QN site [18].
We previously showed that the IC50 value for inhibition of the
cytochrome c reductase activity of the bovine bc1 complex by
ilicicolin H is∼100-fold higher than for the yeast enzyme [9]. In
the current experiments both the bovine and P. denitrificans
enzymes appear to be highly resistant to this inhibitor (Fig. 3B).
Thus the yeast enzymemay contain structural features important
for the binding of this inhibitor that the other two are lacking, or
the bovine and P. denitrificans enzymes may contain features
that confer resistance to the binding of this inhibitor. Funiculosin
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enzymes. It differs from ilicicolin H in that only the bc1 complex
from P. denitrificans is less sensitive towards this inhibitor.
The L198F yeast cytochrome b mutation conferred cross-
resistance towards all three inhibitors in vivo [14], but resistance
was seen in vitro to only ilicicolin H and funiculosin, probably
due to the high affinity of antimycin relative to enzyme concen-
tration in the assay as discussed above. In particular, the effect of
substitution of the leucine by a bulkier phenylalanine on the
inhibition by funiculosin is dramatic. This suggests that this
residue is an important binding determinant for this inhibitor. It is
possible that an isoleucine at this position in the P. denitrificans
enzymemay contribute to weakening of inhibition, but it is more
likely that there are other determinants that are responsible for
this difference. In this regard it is interesting to note that Degli
Esposti and coworkers [26,37] proposed that valine at the posi-
tion equivalent to Val-194 in the yeast cytochrome b is one of the
residues responsible for the intrinsic resistance of fish, rabbit and
horse cytochrome bc1 complexes to funiculosin. However, the
yeast and bovine enzymes, which have valine and alanine,
respectively, at this position in their cytochrome bs, are equally
sensitive to funiculosin (Figs. 2 and 3).
It should also be acknowledged that with all of the cyto-
chrome b mutations the possibility remains that the effect of the
mutational change is indirect, due to structural changes trans-
mitted through the protein to a ligand-binding site some dis-
tance from the mutated residue. A precedent for such long-range
effects might be found in mutational changes to Ala-126 in the
yeast protein, which confer resistance to both center N and
center P inhibitors (cf Ref. [37] and Table IV in Ref. [26]). The
distinction between direct local steric effects and long-range
indirect effects can only be addressed when crystal structures of
the enzymes with ilicicolin and funiculosin bound become
available.
The W30C mutation slightly lowers the sensitivity to
inhibition of the yeast bc1 complex by ilicicolin (Fig. 5), but
has a more pronounced effect on funiculosin inhibition of the
enzyme (Fig. 6). Trp-30 is itself not responsible for the difference
in efficacy of funiculosin inhibition between the enzymes from P.
denitrificans and the two other species, since it is conserved.
However, the effects of theW30Cmutation suggest that Trp-30 is
part of a binding pocket for funiculosin, as was reported pre-
viously [34]. The W30C mutation was originally obtained as a
second site mutation that corrects the respiratory deficient phe-
notype of the S206Lmutant [16]. Two other second sitemutations
in the same revertant screen were obtained, N208Y and N208K,
and the double mutations also confer resistance towards funi-
culosin [38]. The three residues (Trp-30, Ser-206 and Asn-208)
are within 5 Å from each other. The temperature-sensitivity of the
three revertant strains suggests a structural change has occurred
that makes these bc1 complexes more labile, and that may be near
the funiculosin binding site and thus block the binding of
funiculosin.
The Ser-20, Gln-22 and Met-221 residues are within 5 Å of
each other, on the opposite site of the quinone ring with respect
to Trp-30 and Leu-198 (Fig. 1). As was discussed above, Met-
221 in the yeast enzyme and the phenylalanine residue at theequivalent position in the bovine and P. denitrificans complexes
(Figs. 1 and 2) stabilize the binding of the quinone at the QN
site. The M221E and M221Q mutations render the yeast en-
zyme slightly resistant towards ilicicolin H (Fig. 5). One
possible explanation is the importance of a hydrophobic inter-
action for the binding of ilicicolin H. However, the bovine and
P. denitrificans enzymes are much less sensitive towards this
inhibitor, even though a hydrophobic interaction may be pre-
sent. The residues at positions 20 and 22 appear to be especially
important for the binding of ilicicolin H, as discussed below.
Thus, an alternative explanation for the results of the Met-221
variants is that these mutations have modified the conformation
of Ser-20 and Gln-22 and thus weakened the binding of
ilicicolin H.
Ser-20 and Gln-22 are two of the least conserved residues in
the QN site of the three species. The results with the mutant yeast
enzymes indicate that Ser-20 and Gln-22 play an important role
in the different efficacies of ilicicolin H in inhibiting the bc1
complexes from the three species (Fig. 5). The purified bc1
complex from the S20Tmutant and the enzyme in mitochondrial
membranes from the S20L yeast strain [14] are both highly
resistant towards ilicicolin H. Interestingly, leucine is the natu-
rally occurring residue at the equivalent position in the bovine
bc1 complex, while another hydrophobic residue, isoleucine, is
present in the enzyme from P. denitrificans. Both the Q22T and
Q22E mutations also render the yeast enzyme less sensitive to
ilicicolin H. Threonine is again a naturally occurring residue in
one of the species, P. denitrificans.
A straightforward explanation of these comparisons is that
Ser-20 and Gln-22 are critical for the binding of the ilicicolin H
to the yeast bc1 complex. In addition, the nature of the two
residues at these positions appears to modulate the orientation of
the imidazole ring of His-202. In the bovine and R. capsulatus
(and possibly also P. denitrificans, see above) QN site the
imidazole ring is rotated into the quinone binding site. This
configuration may also weaken the binding of ilicicolin.
Replacement of ilicicolin H by antimycin, followed by moni-
toring the spectral changes in the ferro-cytochrome bH spectrum
from the ilicicolin induced blue shift to the antimycin induced
red shift, indeed is much faster in the mutant enzymes than in the
wild-type enzymes (Ref. [9] and unpublished results).
We previously reported the effect of these yeast mutations on
the quinol oxidation reaction at the QN site [28]. Although there
were significant differences in the kinetics of quinol oxidation at
center N, these differences did not compromise the catalytic
function of the enzymes. With the exception of the W30C muta-
tion, the impairment in center N kinetics in these mutants was
attributed to weakened affinity for the quinol substrate at center N.
The altered affinity for the substrate correlates well with the
resistance of the mutants towards ilicicolin H. This suggests that
ilicicolin H occupies a similar binding site as the ubiquinol sub-
strate in the yeast bc1 complex (Fig. 1) that involves the residues
Ser-20, Gln-22, Leu-198 and Met-221. However ilicicolin is a
much larger molecule than ubiquinol and structural perturbations
by these mutations can have a more pronounced effect on the
binding of the inhibitor. For example the L198Fmutation has only
a modest effect on the kinetics at center N, but increases the IC50
218 F.A.J. Rotsaert et al. / Biochimica et Biophysica Acta 1777 (2008) 211–219for ilicicolin H 12-fold. On the other hand the binding site for
funiculosin appears to be slightly different, where the important
residues Leu-198 and Trp-30C are near the bH heme. Ser-20, Gln-
22 andMet-221 appear to play no direct role in the binding of this
inhibitor, but are important for catalysis. The nature of the residues
at positions 20 and 22 is an important determinant for binding of
ilicicolin H and can account for the different efficacies of
inhibition by this inhibitor in the three species.
In conclusion, it should also be noted that the species dif-
ferences noted here might have important consequences for
drug design. Atovaquone, a hydroxynaphthoquinone inhibitor
of the cytochrome bc1 complex, has been used therapeutically
to treat Plasmodium falciparum malaria, Pneumocystis carinii
pneumonia, and Toxoplasma gondii toxoplasmosis. This
inhibitor kills these organisms by blocking ubiquinol oxidation
at center P of the bc1 complex, although its therapeutic effec-
tiveness has been compromised by spontaneously arising muta-
tions that confer resistance to the drug [39]. In principle, it
should also be possible to design drugs targeted to the quinone
reduction site at center N of the enzyme, provided that the
inhibitory compounds display appropriate species selectivity
toward the pathogen versus host enzymes. This would allow the
advantages of a combination drug therapy directed toward a
single essential enzyme target, thus minimizing the likelihood
of side effects. The current results demonstrate that there are
sufficient structural differences between fungal, bacterial, and
mammalian center N sites to permit such drug design.
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